FEDERAL RESERVE SYSTEM

Notice of Proposals To Engage in or To Acquire Companies Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y (12 CFR part 225) to engage de novo, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in §225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than May 17, 2017.

A. Federal Reserve Bank of Boston (Prabal Chakrabarti, Senior Vice President) 600 Atlantic Avenue, Boston, Massachusetts 02210–2204. Comments can also be sent electronically to BOS.SHC.Applications.Comments@bos.frb.org.

1. Narragansett Financial Corp., Swansea, Massachusetts; to retain 80 percent of the voting shares of Plimoth Trust Company, LLC, Plimoth Massachusetts, and thereby engage in trust company activities pursuant to section 225.28(b)(5).

In addition, Plimoth has applied to acquire certain assets and assume certain liabilities from Savings Institute Bank and Trust Company, Willimantic, Connecticut.


Yao-Chin Chao, Assistant Secretary of the Board.

[FR Doc. 2017–08900 Filed 5–2–17; 8:45 am]

BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[CDC–2015–0021; Docket Number NIOSH–153–C]

Issuance of Final Guidance Publications

AGENCY: National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of issuance of final guidance publications.

SUMMARY: NIOSH announces the availability of the following final 5 Skin Notation Profiles: Acrylic acid [CAS No. 79–01–7], Dichlorvos [CAS No. 62–73–7], Morpholine [CAS No. 110–91–8], Ethyl p-nitrophenyl phenylphosphorothioate (EPN) [CAS No. 2104–64–5], Dioxathion [CAS No. 78–34–2].

DATES: The final Skin Notation Profiles documents were published on April 10, 2017.

ADDRESSES: These documents may be obtained at the following link: http://www.cdc.gov/niosh/topics/skin/skin Notation_profiles.html.

FOR FURTHER INFORMATION CONTACT: Naomi Hudson, Dr. P.H., NIOSH, Education and Information Division (EID), Robert A. Taft Laboratories, 1090 Tusculum Ave. MS–C32, Cincinnati, OH 45226, email: iu2w@cdc.gov.

SUPPLEMENTARY INFORMATION: On May 1, 2015, NIOSH published a request for public review in the Federal Register [80 FR 24932] on skin notation profiles and technical documents. All comments received were reviewed and accepted where appropriate.


Frank Hearl, Chief of Staff, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.

[FR Doc. 2017–08887 Filed 5–2–17; 8:45 am]

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Peer Review Meeting.

Date: June 1, 2017.

Time: 2:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, Room 3F40, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).


(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)


Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017–08946 Filed 5–2–17; 8:45 am]

BILLING CODE 4140–01–P